Literature DB >> 18050298

Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.

Marc A Sidler1, Steven T Leach, Andrew S Day.   

Abstract

BACKGROUND: Fecal calprotectin is a sensitive marker for gut inflammation. Recently, we have established that a related protein, S100A12, is elevated in the feces of children with inflammatory bowel disease (IBD). This may represent a specific and sensitive disease marker. The objective was to investigate the utility of fecal S100A12, in comparison to fecal calprotectin and standard inflammatory markers, as a screening marker for IBD in children with gastrointestinal symptoms.
METHODS: Stool samples were obtained from 61 children presenting with gastrointestinal symptoms requiring endoscopy. Fecal S100A12, calprotectin, and serum S100A12 levels were measured and correlated to final diagnosis and standard tests (ESR, CRP, platelet count, and albumin).
RESULTS: Children diagnosed with IBD (n = 31) had elevated fecal S100A12 (median 55.2 mg/kg) and calprotectin (median 1265 mg/kg) levels compared with the children without IBD (n = 30; S100A12: median 1.1 mg/kg, P < 0.0001; calprotectin: median 30.5 mg/kg; P < 0.0001). The sensitivity and specificity of fecal S100A12 (cutoff 10 mg/kg) for the detection of IBD were both 97%, whereas fecal calprotectin (cutoff 50 mg/kg) gave a sensitivity of 100% and a specificity of 67%.
CONCLUSIONS: Both fecal markers were superior to the sensitivities and specificities of any standard inflammatory test. Both fecal S100A12 and calprotectin are sensitive markers of gastrointestinal inflammation, but fecal S100A12 provided exceptional specificity in distinguishing children with IBD from children without IBD. Fecal S100A12 is a simple, noninvasive test that can be used to screen and select children warranting further invasive and laborious procedures such as endoscopy for the investigation of their gastrointestinal symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18050298     DOI: 10.1002/ibd.20336

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  48 in total

1.  Fecal M2-PK in children with Crohn's disease: a preliminary report.

Authors:  A S Day; T Judd; D A Lemberg; S T Leach
Journal:  Dig Dis Sci       Date:  2012-06-27       Impact factor: 3.199

Review 2.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

3.  Induction of nuclear factor-κB responses by the S100A9 protein is Toll-like receptor-4-dependent.

Authors:  Matteo Riva; Eva Källberg; Per Björk; Dora Hancz; Thomas Vogl; Johannes Roth; Fredrik Ivars; Tomas Leanderson
Journal:  Immunology       Date:  2012-10       Impact factor: 7.397

Review 4.  Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Elisavet K Tiaka; Spyros P Potamianos
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.199

5.  Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.

Authors:  Erin H Seeley; Mary K Washington; Richard M Caprioli; Amosy E M'Koma
Journal:  Proteomics Clin Appl       Date:  2013-05-08       Impact factor: 3.494

6.  C-reactive protein and disease activity in children with Crohn's disease.

Authors:  Samantha Tilakaratne; Daniel A Lemberg; Steven T Leach; Andrew S Day
Journal:  Dig Dis Sci       Date:  2010-01       Impact factor: 3.199

7.  Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.

Authors:  Jernej Dolinšek; Petra Rižnik; Larisa Sabath; Dušanka Mičetić-Turk
Journal:  Wien Klin Wochenschr       Date:  2015-12-10       Impact factor: 1.704

8.  Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Panagiotis Georgoulias; Chara Tzavara; Varvara Valotassiou; Anastasia Kapsoritaki; Spyros P Potamianos
Journal:  BMC Gastroenterol       Date:  2010-10-14       Impact factor: 3.067

Review 9.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 10.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.